| Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1/FXR signaling S Marchianò, M Biagioli, R Roselli, A Zampella, C Di Giorgio, M Bordoni, ... Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids …, 2022 | 13 | 2022 |
| Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a model of NASH S Marchianò, M Biagioli, E Morretta, C Di Giorgio, R Roselli, M Bordoni, ... Scientific reports 13 (1), 1602, 2023 | 12 | 2023 |
| Next-generation sequencing analysis of gastric cancer identifies the leukemia inhibitory factor receptor as a driving factor in gastric cancer progression and as a predictor of … C Di Giorgio, S Marchianò, E Marino, M Biagioli, R Roselli, M Bordoni, ... Frontiers in Oncology 12, 939969, 2022 | 8 | 2022 |
| Discovery of BAR502, as potent steroidal antagonist of leukemia inhibitory factor receptor for the treatment of pancreatic adenocarcinoma C Di Giorgio, R Bellini, A Lupia, C Massa, M Bordoni, S Marchianò, ... Frontiers in Oncology 13, 1140730, 2023 | 5 | 2023 |
| Activation of GPBAR1 attenuates vascular inflammation and atherosclerosis in a mouse model of NAFLD-related cardiovascular disease M Biagioli, S Marchianò, C Di Giorgio, M Bordoni, G Urbani, R Bellini, ... Biochemical Pharmacology 218, 115900, 2023 | 4 | 2023 |
| Repositioning mifepristone as a leukaemia inhibitory factor receptor antagonist for the treatment of pancreatic adenocarcinoma C Di Giorgio, A Lupia, S Marchianò, M Bordoni, R Bellini, C Massa, ... Cells 11 (21), 3482, 2022 | 4 | 2022 |
| Bile acids and bile acid activated receptors in the treatment of COVID-19 S Fiorucci, G Urbani, M Biagioli, V Sepe, E Distrutti, A Zampella Biochemical Pharmacology, 115983, 2023 | 2 | 2023 |
| The leukemia inhibitory factor regulates fibroblast growth factor receptor 4 transcription in gastric cancer C Di Giorgio, R Bellini, A Lupia, C Massa, G Urbani, M Bordoni, ... Cellular Oncology, 1-16, 2023 | 1 | 2023 |
| Bile Acids and SARS-CoV-2: Ursodeoxycholic Acid as a Potential Treatment of COVID-19 S Fiorucci, G Urbani, E Distrutti Recent Advances in Inflammation & Allergy Drug Discovery 17 (1), 2-6, 2023 | 1 | 2023 |
| GDF15 in Vascular and Liver Metabolic Disorders: A Novel Therapeutic Target S Fiorucci, G Urbani Recent Advances in Inflammation & Allergy Drug Discovery 16 (2), 55-59, 2022 | 1 | 2022 |
| Role of mRAGEs and ACE2 in SARS-CoV-2-Related Inflammation S Fiorucci, G Urbani Recent Advances in Inflammation & Allergy Drug Discovery 16 (1), 2-4, 2022 | 1 | 2022 |
| How Smell Regulates Metabolism: The Role Of Ectopically Expressed Olfactory Receptors In Lipid and Glucose Homeostasis G Urbani, E Distrutti, M Biagioli, S Marchianò, S Fiorucci Preprints, 2022 | 1 | 2022 |
| Tu1726 GPBAR1 AGONISM AND SIMULTANEOUS RORΓT INVERSE AGONISM AS A NOVEL PROMISING THERAPY FOR THE TREATMENT OF IBD M Biagioli, C Di Giorgio, S Marchianò, R Bellini, C Massa, M Bordoni, ... Gastroenterology 166 (5), S-1396, 2024 | | 2024 |
| Su1492 BILE ACIDS AS ENDOGENOUS ANTAGONISTS OF LEUKEMIA INHIBITORY FACTOR RECEPTOR (LIFR) IN GASTRIC CANCER (GC): IMPLICATIONS FOR THERAPEUTIC INTERVENTIONS C Di Giorgio, E Morretta, A Lupia, R Bellini, C Massa, G Urbani, M Bordoni, ... Gastroenterology 166 (5), S-762-S-763, 2024 | | 2024 |
| Sa1563 BAR502 AS A PROMISING THERAPY FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS: INSIGHTS FROM MURINE MODEL STUDIES S Marchianò, M Biagioli, C Di Giorgio, G Urbani, M Bordoni, R Bellini, ... Gastroenterology 166 (5), S-476, 2024 | | 2024 |
| 774 FXR AGONISM AND PRIMARY BILE ACIDS: DRIVERS OF IMMUNEESCAPE IN INTESTINAL GASTRIC CANCER (GC) C Di Giorgio, M Biagioli, S Marchianò, L Cari, R Bellini, G Urbani, ... Gastroenterology 166 (5), S-187-S-188, 2024 | | 2024 |
| 913 THE BILE ACIDS METABOLITES PRODUCED BY THE INTESTINAL MICROBIOTA ACT AS GPBAR1 AGONIST AND RORΓT INVERSE AGONIST DETERMINING THE COURSE OF INFLAMMATORY BOWEL DISEASE M Biagioli, C Di Giorgio, C Massa, S Marchianò, R Bellini, M Bordoni, ... Gastroenterology 166 (5), S-222, 2024 | | 2024 |
| Bile acids serve as endogenous antagonists of the Leukemia inhibitory factor (LIF) receptor in oncogenesis C Di Giorgio, E Morretta, A Lupia, R Bellini, C Massa, G Urbani, M Bordoni, ... Biochemical Pharmacology 223, 116134, 2024 | | 2024 |
| A microbial derived bile acid acts as GPBAR1 agonist and RORγt inverse agonist and reverses inflammation in inflammatory bowel disease M Biagioli, C Di Giorgio, C Massa, S Marchiano', R Bellini, M Bordoni, ... bioRxiv, 2024.04. 08.588556, 2024 | | 2024 |
| Defective Bile Acid Signaling Promotes Vascular Dysfunction, Supporting a Role for G‐Protein Bile Acid Receptor 1/Farnesoid X Receptor Agonism and Statins in the Treatment of … S Marchianò, M Biagioli, M Bordoni, E Morretta, C Di Giorgio, V Vellecco, ... Journal of the American Heart Association 12 (23), e031241, 2023 | | 2023 |
